Treatment-related toxicity and symptom-related bother following postoperative radiotherapy for prostate cancer

Journal of the Canadian Urological Association

Volumn 4, Issue 2, 2010, Pages 105-111

  Sia, Michael ^a   Rodrigues, George ^b   Menard, Cynthia ^a   Bayley, Andrew ^a   Bristow, Robert ^a   Chung, Peter ^a   Gospodarowicz, Mary ^a   Milosevic, Michael ^a   Warde, Padraig ^a   Catton, Charles ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77951181217     PISSN: 19116470     EISSN: 19116470     Source Type: Journal    
DOI: 10.5489/cuaj.801     Document Type: Article

References (37)

1. Thompson I, Tangen C, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces metastases and improves survival: Long term followup of a randomized trial. J Urol 2009;181:956-62.
2. Thompson IJ, Tangen C, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006;296:2329-35.
3. Bolla M, van Poppel H, Collette L, et al. European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005;366:572-8.
4. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Ocol 2009;27:2924-30.
5. Stephenson A, Scardino P, Kattan M, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25:2035-41.
6. Parker C, Sydes M, Catton C, et al. Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy. BJU Int 2007;99:1376-9.
7. Thompson I, Tangen C, Miller G, et al. Adjuvant radiotherapy for pathologic T3 prostate cancer: Results of a randomized, prospective clinical trial with metastases-free survival endpoint. J Urol 2005; 173 suppl(4): Abstract1665.
8. Feng M, Hanlon A, Pisansky T, et al. Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int J Radiat Oncol Biol Phys 2007;68:1417-23.
9. Choo R, Pearse M, Danjoux C, et al. Analysis of gastrointestinal and genitourinary morbidity of postoperative radiotherapy for pathologic T3 disease or positive surgical margins after radical prostatectomy using national cancer institute expanded common toxicity criteria. Int J Radiat Oncol Biol Phys 2008;72:989-95.
10. Parker C, Warde P, Catton C. Salvage radiotherapy for PSA failure after radical prostatectomy. Radiother Oncol 2001;61:107-16.
11. De Meerleer G, Fonteyne V, Meersschout S, et al. Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy. Radiother Oncol 2008;89:205-13.
12. Litwin M, Hays R, Fink A, et al. Quality-of-life outcomes in men treated for localized prostate cancer JAMA 1995;273:129-35.
13. Hu J, Elkin E, Pasta D, et al. Predicting quality of life after radical prostatectomy: results from CaPSURE. J Urol 2004;171(2 Pt 1):703-7.
14. Litwin M, Gore J, Kwan L, et al. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer 2007;109:2239-47.
15. Davis J, Kuban D, Lynch D, et al. Quality of life after treatment for localized prostate cancer: differences based on treatment modality. J Urol 2001;166:947-52.
16. Sanda M, Dunn R, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250-61.
17. Lee W, Hall M, McQuellon R, et al. A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2001;51:614-23.
18. Rodrigues G, Bauman G, Lock M, et al. Psychometric properties of a prostate cancer radiation late toxicity questionnaire. Health Qual Life Outcomes 2007;5:29. Available at: http://www.hqlo.com/content/5/1/29 (Accessed February 24, 2010).
19. Storey M, Pollack A, Zagars G, et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomised trial. Int J Radiat Oncol Biol Phys 2000;48:635-42.
20. Wei J, Dunn R, Litwin M, et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000;56:899-905.
21. Esper P, Mo F, Chodak G, et al. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 1997;50:920-8.
22. Potosky A, Harlan L, Stanford J, et al. Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 1999;91:1719-24.
23. Borghede G, Sullivan M. Measurement of quality of life in localized prostatic cancer patients treated with radiotherapy. Development of a prostate cancer-specific module supplementing the EORTC QLQC30. Qual Life Res 1996;5:212-22.
24. Shrader-Bogen C, Kjellberg J, McPherson C, et al. Quality of life and treatment outcomes: prostate carcinoma patients' perspectives after prostatectomy or radiation therapy. Cancer 1997;79:1977-86.
25. Crook J, Esche B, Futter N. Effect of pelvic radiotherapy for prostate cancer on bowel, bladder, and sexual function: the patient's perspective. Urology 1996;47:317-94.
26. Skala M, Rosewall T, Dawson L, et al. Patient-assessed late toxicity rates and principal component analysis after image-guided radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2007;68:690-8.
27. Nichol A, Chung P, Lockwood G, et al. A phase II study of localized prostate cancer treated to 75.6 Gy with 3D conformal radiotherapy. Radiother Oncol 2005;76:11-7.
28. Moinpour C, Hayden K, Unger J, et al. Southwest Oncology Group. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J Clin Ocol 2008;26:112-20.
29. Pearse M, Choo R, Danjoux C, et al. Prospective assessment of gastrointestinal and genitourinary toxicity of salvage radiotherapy for patients with prostate-specific antigen relapse or local recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys 2008;72:792-8.
30. Pinkawa M, Fischedick K, Asadpour B, et al. Health-related quality of life after adjuvant and salvage postoperative radiotherapy for prostate cancer a prospective analysis. Radiother Oncol 2008;88:135-9.
31. Peeters S, Heemsbergen W, van Putten W, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 2005;61:1019-34.
32. Litwin M, Flanders S, Pasta D, et al. Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 1999;54:503-8.
33. Penson D, McLerran D, Feng Z,, et al. 5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. J Urol 2008;179(5 Suppl):S40-4.
34. Miller D, Wei J, Dunn R, et al. Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: potential influence of sexual motivation and/or indifference. Urology 2006;68:166-71.
35. Mulhall J, Morgentaler A. Penile rehabilitation should become the norm for radical prostatectomy patients. J Sex Med 2007;4:538-43.
36. Mulhall J, Slovick R, Hotaling J, et al. Erectile dysfunction after radical prostatectomy: hemodynamic profiles and their correlation with the recovery of erectile function. J Urol 2002;167:1371-5.
37. Wiltshire K, Brock K, Haider M, et al. Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy. Int J Radiat Oncol Biol Phys 2007;69:1090-9.